Neurocrine Biosciences | NBIX - Les Charges D'Exploitation





Les Charges D'Exploitation Changement Date
AbbVie USD 10.27B 1000K 2026-06
Acadia Pharmaceuticals USD 270.12M 2.55M 2026-06
Agios Pharmaceuticals USD 130.77M 10.77M 2026-03
ALKERMES USD 1.81B 57.02M 2026-06
Alnylam Pharmaceuticals USD 1.06B 160.97M 2026-06
Amgen USD 11.69B 6.9B 2026-06
Biogen USD 2.98B 1.02B 2026-06
BioMarin Pharmaceutical USD 6.32B 5.69B 2026-06
Cytokinetics USD 207.8M 7.22M 2026-06
Enanta Pharmaceuticals USD 126.59M 346.51M 2025-12
Exelixis USD 380.28M 20.8M 2026-06
Gilead Sciences USD 3.95B 19.57B 2026-06
Halozyme Therapeutics USD 193.34M 1.15M 2026-06
Incyte USD 973.64M 4.65B 2026-06
Ionis Pharmaceuticals USD 370.24M 6.24M 2026-06
Nektar Therapeutics USD 49.12M 8.22M 2026-03
Neurocrine Biosciences USD 739.1M 139.2M 2026-06
Pfizer USD 85.19B 4.91B 2026-06
Prothena USD 25.29M 1.94M 2026-03
Regeneron Pharmaceuticals USD 31.71B 287.8M 2026-06
Repligen USD 183M 8.72M 2026-06
Rigel Pharmaceuticals USD 117.61M 35.67M 2025-09
Sarepta Therapeutics USD 387.96M 15.59M 2026-06
Teva Pharmaceutical Industries USD 3.92B 691M 2026-06
Ultragenyx Pharmaceutical USD 289M 16M 2026-06
Vertex Pharmaceuticals USD 2.07B 217.1M 2026-06